David Turbay, MD
Cardiovascular Disease · El Paso, TXNPI 1922082411
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $122,049 of the $174,737 with a category attached, or 69.8%. 42 manufacturers reported payments, led by Boehringer Ingelheim at 47.5% of the total. Reporting peaked in 2024 at $35,671 and has fallen 52.6% since, to $16,918 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,259 payments — averaging $138.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$83K
- AstraZeneca$29K
- Lilly USA, LLC$13K
- Novo Nordisk$11K
- Novartis$10K
- Abbott$6K
- plus $22K from 36 others
Across 43 payments — averaging $36,435 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$924K
- Amgen$317K
- AstraZeneca$218K
- Astrazeneca UK Limited$108K
What the payments were for
- Consulting fees$15,5569%
- Speaking & faculty fees$122,04970%
- Travel & lodging$14,8428%
- Food & beverage$22,27713%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$92,147
- FARXIGA$27,992
- ENTRESTO$6,625
- FUROSCIX$4,915
- Repatha$4,318
- AVEIR$2,775
- Micra$1,833
- LEQVIO$1,363
- Barostim Neo System$1,223
- EMBLEM MRI S-ICD$559
- Confirm Rx$251
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$144
- ECM Patch,Pouch$143
- COBALT DR MRI SURESCAN$141
- COREVALVE EVOLUT R$140
- MOUNJARO$125
- EVENITY$124
- CAMZYOS$122
- Merlin Connectivity and Remote$115
- Fortify Assura, Ellipse ICD$109
How this compares
$174,737 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,058 | $893,683 |
| EntrestoSacubitril/Valsartan | 857 | $748,215 |
| JardianceEmpagliflozin | 896 | $734,962 |
| WainuaEplontersen Sodium | 16 | $690,616 |
| FarxigaDapagliflozin Propanediol | 619 | $464,754 |
| VyndamaxTafamidis | 16 | $372,458 |
| OpsumitMacitentan | 14 | $200,699 |
| MultaqDronedarone Hcl | 121 | $126,372 |
| OzempicSemaglutide | 98 | $111,192 |
| XareltoRivaroxaban | 59 | $60,298 |
| Repatha SureclickEvolocumab | 88 | $59,159 |
| Repatha PushtronexEvolocumab | 65 | $56,878 |
| KerendiaFinerenone | 48 | $38,137 |
| DapagliflozinDapagliflozin Propanediol | 58 | $29,717 |
| VascepaIcosapent Ethyl | 29 | $17,854 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $1,353 | $1,266,1401,074 claims |
| AstraZenecaWainua, Farxiga, Brilinta | $29,477 | $1,170,370664 claims |
| NovartisEntresto | $9,895 | $748,215857 claims |
| Boehringer IngelheimJardiance | $82,990 | $734,962896 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $695 | $200,69914 claims |
| Sanofi-aventis U.S. LLCMultaq | $47 | $126,372121 claims |
| Novo NordiskOzempic | $11,366 | $111,19298 claims |
| Johnson & JohnsonXarelto | $374 | $60,29859 claims |
| BayerKerendia | $403 | $38,13748 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in El Paso
- Venkatachalam MulukutlaEl Paso$157K
- Juan TaverasEl Paso$91K
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.